Poxel Reports Q2 2026 Revenue Growth but Delays Financial Statements
Event summary
- Poxel reported Q2 2026 consolidated turnover of €1.24M, up from €1.00M in Q2 2025.
- TWYMEEG® sales in Japan grew 32% YoY to ¥2.9B (€15.5M) for Q2 2026.
- Sumitomo Pharma forecasts TWYMEEG® net sales could exceed ¥10B in FY2026, triggering Poxel royalties.
- Poxel postponed its 2025 financial statements and AGM due to debt valuation complexities.
The big picture
Poxel's Q2 2026 results highlight its reliance on TWYMEEG® royalties, while the financial statement delay underscores ongoing debt restructuring challenges. The company's strategic focus remains on monetizing its metabolic disease pipeline through partnerships and asset sales. Sumitomo Pharma's forecasted growth positions TWYMEEG® as a key revenue driver, but Poxel must navigate complex debt valuations to maintain investor confidence.
What we're watching
- Royalty Monetization
- Whether Poxel can sustain double-digit TWYMEEG® growth to meet OrbiMed repayment obligations.
- Debt Valuation
- The pace at which Poxel resolves its debt valuation issues and publishes delayed financial statements.
- Pipeline Progress
- How the Scynexis acquisition of PXL770 will impact Poxel's rare disease revenue streams.